Advanced Notice of Proposed Rulemaking: Medicare Program; Ensuring Safety through Domestic Security with Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals (CMS-1516-ANPRM) - Responded to various issues and proposals provided in the ANPRM, encouraged non-budget neutral Medicare payments to incentivize domestic procurement Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program (Docket No.: CMS-2025-1393) - Responded to various issues in the proposed rule regarding the Medicare Advantage/Part C and the Medicare Prescription Drug Benefit (Part D) program and Quality Rating System (Star Ratings). Global Benchmark for Efficient Drug Pricing (GLOBE) Model Proposed Rule (CMS5545-P) - Responded to various issues and proposals provided in the Proposed Rule, emphasized aligning reimbursement model with performance Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program Proposed Rule (CMS-9883-P) - Responded to various issues and proposals provided in the Proposed Rule Provider payment - Supported changes to Medicare/Medicaid provider payment system and increased hospital reimbursements. Advocated for reimbursement rates that reflect the true cost of care, particularly for hospitals serving vulnerable and rural populations.
Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178). Draft Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (Docket No. FDA-2011-D-0605) - Urging FDA to streamline biosimilar approval for increased patient access to cost-effective treatment alternatives Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Monitored development and introduction of the Drug Origin Transparency Act of 2025 (HR.8339) Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications
Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)
Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)